


PRODUCT INFORMATION



ARQ 092

Item No. 21388

CAS Registry No.: 1313881-70-7
Formal Name: 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl]-2-pyridinamine
MF: C₂₇H₂₄N₆
FW: 432.5
Purity: ≥98%
UV/Vis.: λ_{max}: 344 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

ARQ 092 is supplied as a crystalline solid. A stock solution may be made by dissolving the ARQ 092 in the solvent of choice, which should be purged with an inert gas. ARQ 092 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of ARQ 092 in these solvents is approximately 0.3, 10, and 12.5 mg/ml, respectively.

ARQ 092 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ARQ 092 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. ARQ 092 has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

ARQ 092 is an allosteric, orally bioavailable, pan-Akt inhibitor (IC₅₀s = 5.0, 4.5, and 16 nM for Akt1, Akt2, and Akt3, respectively).¹ It is selective for Akt isoforms over a panel of 303 other kinases.¹ ARQ 092 binds inactive Akt and prevents membrane localization and full Akt activation.^{1,2} It also directly inhibits the membrane-associated active form of Akt, preventing phosphorylation of downstream targets.^{1,2} ARQ 092 inhibits the proliferation of a wide range of cancer cells *in vitro*, inhibits the mutated Akt form found in Proteus syndrome, and attenuates heterotypic cell-cell interactions in a mouse model of sickle cell disease.¹⁻⁴

References

1. Yu, Y., Savage, R.E., Eathiraj, S., *et al.* Targeting AKT1-E17K and the PI3K/AKT pathway with an allosteric AKT inhibitor, ARQ 092. *PLoS One* **10**(10), e0140479 (2015).
2. Lapiere, J.-M., Eathiraj, S., Vensel, D., *et al.* Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An orally bioavailable, selective, and potent allosteric AKT inhibitor. *J. Med. Chem.* **59**(13), 6455-6469 (2016).
3. Kim, K., Li, J., Barazia, A., *et al.* ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease. *Haematologica* **102**(2), 246-259 (2016).
4. Lindhurst, M.J., Yourick, M.R., Yu, Y., *et al.* Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome. *Sci. Rep.* **5**(17162) (2015).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/01/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM